Accurate Categorisation of Menopausal Status for Research Studies: a Step-by-step Guide and Detailed Algorithm Considering Age, Self-reported Menopause and Factors Potentially Masking the Occurrence of Menopause

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2022 Mar 5

PMID 35246240

Authors

Sarsha Yap

Amy Vassallo

David E Goldsbury

Usha Salagame

Louiza Velentzis

Emily Banks

Dianne L OConnell

Karen Canfell

Julia Steinberg

Affiliations

Soon will be listed here.

Abstract

Objective: Menopausal status impacts risk for many health outcomes. However, factors including hysterectomy without oophorectomy and Menopausal Hormone Therapy (MHT) can mask menopause, affecting reliability of self-reported menopausal status in surveys. We describe a step-by-step algorithm for classifying menopausal status using: directly self-reported menopausal status; MHT use; hysterectomy; oophorectomy; intervention timing; and attained age. We illustrate this approach using the Australian 45 and Up Study cohort (142,973 women aged ≥ 45 years).

Results: We derived a detailed seven-category menopausal status, able to be further consolidated into four categories ("pre-menopause"/"peri-menopause"/"post-menopause"/"unknown") accounting for participants' ages. 48.3% of women had potentially menopause-masking interventions. Overall, 93,107 (65.1%), 9076 (6.4%), 17,930 (12.5%) and 22,860 (16.0%) women had a directly self-reported "post-menopause", "peri-menopause", "pre-menopause" and "not sure"/missing status, respectively. 61,464 women with directly self-reported "post-menopause" status were assigned a "natural menopause" detailed derived status (menopause without MHT use/hysterectomy/oophorectomy). By accounting for participants' ages, 105,817 (74.0%) women were assigned a "post-menopause" consolidated derived status, including 15,009 of 22,860 women with "not sure"/missing directly self-reported status. Conversely, 3178 of women with directly self-reported "post-menopause" status were assigned "unknown" consolidated derived status. This algorithm is likely to improve the accuracy and reliability of studies examining outcomes impacted by menopausal status.

Citing Articles

Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.

Mastrantoni L, Garufi G, Giordano G, Maliziola N, Di Monte E, Arcuri G NPJ Breast Cancer. 2025; 11(1):11.

PMID: 39910103 PMC: 11799161. DOI: 10.1038/s41523-025-00727-w.

Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer.

Basmadjian R, Lupichuk S, Xu Y, Quan M, Cheung W, Brenner D JAMA Netw Open. 2024; 7(3):e242082.

PMID: 38477918 PMC: 10938175. DOI: 10.1001/jamanetworkopen.2024.2082.

Cancer therapy-related vaginal toxicity: its prevalence and assessment methods-a systematic review.

Claes M, Tuts L, Robijns J, Mulders K, Van De Werf E, Bulens P J Cancer Surviv. 2024; .

PMID: 38383907 DOI: 10.1007/s11764-024-01553-y.

In Primary Aldosteronism Acute Potassium Chloride Supplementation Suppresses Abundance and Phosphorylation of the Sodium-Chloride Cotransporter.

Wu A, Wolley M, Matthews A, Cowley D, Welling P, Fenton R Kidney360. 2022; 3(11):1909-1923.

PMID: 36514401 PMC: 9717638. DOI: 10.34067/KID.0003632022.

Pathways to diagnosis of endometrial and ovarian cancer in the 45 and Up Study cohort.

Yap S, Vassallo A, Goldsbury D, OConnell D, Brand A, Emery J Cancer Causes Control. 2022; 34(1):47-58.

PMID: 36209449 PMC: 9816254. DOI: 10.1007/s10552-022-01634-2.

References

Banks E, Redman S, Jorm L, Armstrong B, Bauman A, Beard J . Cohort profile: the 45 and up study. Int J Epidemiol. 2007; 37(5):941-7. PMC: 2557061. DOI: 10.1093/ije/dym184. View

. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204):1159-1168. PMC: 6891893. DOI: 10.1016/S0140-6736(19)31709-X. View

Gold E . The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am. 2011; 38(3):425-40. PMC: 3285482. DOI: 10.1016/j.ogc.2011.05.002. View

Colditz G, Stampfer M, Willett W, Stason W, Rosner B, Hennekens C . Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol. 1987; 126(2):319-25. DOI: 10.1093/aje/126.2.319. View

Triebner K, Johannessen A, Svanes C, Leynaert B, Benediktsdottir B, Demoly P . Describing the status of reproductive ageing simply and precisely: A reproductive ageing score based on three questions and validated with hormone levels. PLoS One. 2020; 15(6):e0235478. PMC: 7326235. DOI: 10.1371/journal.pone.0235478. View

. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012; 13(11):1141-51. PMC: 3488186. DOI: 10.1016/S1470-2045(12)70425-4. View

Cooper G, Thorp Jr J . FSH levels in relation to hysterectomy and to unilateral oophorectomy. Obstet Gynecol. 1999; 94(6):969-72. DOI: 10.1016/s0029-7844(99)00429-9. View

Velentzis L, Banks E, Sitas F, Salagame U, Tan E, Canfell K . Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study. PLoS One. 2016; 11(3):e0146494. PMC: 4805183. DOI: 10.1371/journal.pone.0146494. View

Wilson L, Pandeya N, Byles J, Mishra G . Hysterectomy status and all-cause mortality in a 21-year Australian population-based cohort study. Am J Obstet Gynecol. 2018; 220(1):83.e1-83.e11. DOI: 10.1016/j.ajog.2018.10.002. View

10.

de Medeiros S, Yamamoto M, Barbosa J . Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health. 2014; 6:13-24. PMC: 3941181. DOI: 10.4137/CMWH.S10483. View

11.

Arriaga M, Vajdic C, Canfell K, MacInnis R, Banks E, Byles J . The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study. Int J Cancer. 2019; 145(9):2383-2394. DOI: 10.1002/ijc.32231. View

12.

Banks E, Beral V, Cameron R, Hogg A, LANGLEY N, Barnes I . Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat. 2002; 6(4):357-63. DOI: 10.1080/13595220152601837. View

13.

Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362(9382):419-27. DOI: 10.1016/s0140-6736(03)14065-2. View

14.

. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

15.

Harlow S, Gass M, Hall J, Lobo R, Maki P, Rebar R . Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012; 15(2):105-14. PMC: 3580996. DOI: 10.3109/13697137.2011.650656. View

16.

. Variations in reproductive events across life: a pooled analysis of data from 505 147 women across 10 countries. Hum Reprod. 2019; 34(5):881-893. PMC: 7571491. DOI: 10.1093/humrep/dez015. View

17.

Phipps A, Ichikawa L, Bowles E, Carney P, Kerlikowske K, Miglioretti D . Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates. Maturitas. 2010; 67(1):60-6. PMC: 2922404. DOI: 10.1016/j.maturitas.2010.04.015. View

18.

Salagame U, Banks E, Sitas F, Canfell K . Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study. Int J Cancer. 2015; 138(8):1905-14. DOI: 10.1002/ijc.29942. View